No abstract available
MeSH terms
-
Adenocarcinoma / blood
-
Adenocarcinoma / drug therapy*
-
Aged
-
Androgen Antagonists / adverse effects*
-
Androgen Antagonists / therapeutic use
-
Anemia / chemically induced*
-
Anemia / drug therapy
-
Anemia / physiopathology
-
Antineoplastic Agents, Hormonal / adverse effects*
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Erythrocyte Count*
-
Erythropoiesis / drug effects*
-
Erythropoietin / physiology
-
Erythropoietin / therapeutic use
-
Humans
-
Insulin-Like Growth Factor I / physiology*
-
Male
-
Middle Aged
-
Prostatic Neoplasms / blood
-
Prostatic Neoplasms / drug therapy*
-
Receptor, IGF Type 1 / physiology*
-
Recombinant Proteins
-
Testosterone / deficiency
-
Testosterone / physiology
Substances
-
Androgen Antagonists
-
Antineoplastic Agents, Hormonal
-
Recombinant Proteins
-
Erythropoietin
-
Testosterone
-
Insulin-Like Growth Factor I
-
Receptor, IGF Type 1